Temazepam updated on 02-10-2025

Oro-facial clefts

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S17674
R74626		 Laspro, 2024 Oral clefts (ICD 10 codes Q35 or Q36 or Q37) during pregnancy (anytime or not specified) excluded nested case control unexposed (general population or NOS) Adjustment: No BZD Coexposure: Not specified 1.14 [0.61;2.13]
excluded (exposition period) 		10/-   12,088/- 12,098 -
ref
S15331
R63146		 Ban (Other indications) (Controls unexposed, disease free), 2014 Oro-facial cleft 1st trimester retrospective cohort (claims database) unexposed, disease free excluded Adjustment: No BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) 1.00 [0.06;16.03] C
excluded (control group) 		0/379   464/351,785 464 379
ref
S15329
R63116		 Ban (Other indications) (Controls unexposed, sick), 2014 Oro-facial cleft 1st trimester retrospective cohort (claims database) unexposed, sick Adjustment: No BZD Coexposure: No (among psychiatric (ATD and/or psychotropics) medications) Indication BZD: Psychiatric diseases (depression, anxiety, ...) 0.71 [0.04;11.64] C 0/379   35/19,193 35 379
ref
Total 1 studies 0.71 [0.04;11.64] 35 379
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Ban (Other indications) (Controls unexposed, sick), 2014Ban, 2014 1 0.71[0.04; 11.64]353790%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: moderateROB mesure: unclearROB reporting: moderate0.22.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Other indications) (Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 1 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 1 Tags Adjustment   - No  - No 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 1 BZD Coexposure   - No (among psychiatric (ATD and/or p ...  - No (among psychiatric (ATD and/or psychotropics) medications) 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 1 Indication BZD   - Psychiatric diseases (depression, a ...  - Psychiatric diseases (depression, anxiety, ...) 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 1 All studiesAll studies 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 10.210.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 15331

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.00[0.06; 16.03]464379 -NABan (Other indications) (Controls unexposed, disease free), 2014 1 unexposed, sick controlsunexposed, sick controls 0.71[0.04; 11.64]35379 -NABan (Other indications) (Controls unexposed, sick), 2014 10.510.01.0